To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.

Phase 2

Completed

• Conditions: Epilepsy, Partial

• Registration Number: NCT00141414
• Lead Sponsor: Pfizer

Brief Summary

To evaluate the long-term safety of pregabalin in refractory partial epilepsy.

Detailed Description

Not available

Study Timeline

• Study Start: 1997-11
• Study First Submitted: 2005-08-30
• Study First Submitted QC: 2005-08-30
• Study First Posted: 2005-09-01
• Study Completion: 2005-10
• Status Verified: 2006-12
• Last Update Submitted: 2006-12-28
• Last Update Posted: 2007-01-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 82

Inclusion Criteria

• Must have met the inclusion criteria for preceding double-blind study.
• Have received double-blind study medication and wish to receive open-label pregabalin.

Exclusion Criteria

• Pregnant or considering becoming pregnant.
• Receiving any concomitant medication that could alter the effectiveness of their medication response or seizure frequency.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Safety

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇩🇪 Bonn, Germany